HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy.

AuthorsValeria Gerthofer, Alexander Scheiter, Florian Lüke, Felix Keil, Kirsten Utpatel, Laura-Maria-Giovanna Pöhmerer, Johannes Seitz, Christoph Niessen, Atanas Ignatov, Wolfgang Dietmaier, Diego F Calvisi, Matthias Evert, Olaf Ortmann, Stephan Seitz
JournalJCO precision oncology (JCO Precis Oncol) Vol. 5 ( 2021) ISSN: 2473-4284 [Electronic] United States
PMID34568722 (Publication Type: Case Reports)
Chemical References
  • Antineoplastic Agents
  • Calmodulin-Binding Proteins
  • Membrane Proteins
  • Nerve Tissue Proteins
  • Organophosphorus Compounds
  • Pyrimidines
  • STRN protein, human
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • brigatinib
Topics
  • Abdominal Pain (etiology)
  • Anaplastic Lymphoma Kinase (analysis, genetics)
  • Antineoplastic Agents (therapeutic use)
  • Calmodulin-Binding Proteins (analysis, genetics)
  • Crizotinib (therapeutic use)
  • Female
  • Humans
  • Membrane Proteins (analysis, genetics)
  • Mesothelioma, Malignant (drug therapy)
  • Nerve Tissue Proteins (analysis, genetics)
  • Organophosphorus Compounds (therapeutic use)
  • Peritoneum (abnormalities, drug effects, physiopathology)
  • Pyrimidines (therapeutic use)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: